Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.
Journal: Leukemia & lymphoma
Published: July 10, 2026
A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma.
Journal: Current medical research and opinion
Published: June 25, 2026
A mortality model for relapsed or refractory multiple myeloma: emulation of subjective life expectancy criteria from a clinical trial in real-world data.
Journal: Annals of hematology
Published: November 11, 2025
Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.
Journal: Cancer
Published: November 04, 2025
Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 29, 2025
Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses.
Journal: Clinical lymphoma, myeloma & leukemia
Published: September 23, 2025
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States.
Journal: Blood cancer journal
Published: August 07, 2025
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.
Journal: Blood cancer journal
Published: August 07, 2025
Patient preferences for triple-class-exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study.
Journal: Future oncology (London, England)
Published: February 27, 2025
Last Updated: 09/26/2026